title: Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer.
abstract: We treated 28 patients who had no prior chemotherapy for stage IV breast cancer and 51 patients with extensive prior exposure to other chemotherapeutic agents with a 24-hour infusion of Taxol (paclitaxel) as a single agent. Prophylactic recombinant human granulocyte colony-stimulating factor was administered routinely to ameliorate the anticipated dose-limiting toxicity of neutropenia. Nonhematologic toxicity was mild to moderate in most cases. Taxol was more active in patients with chemotherapy-naive stage IV disease, but activity was also observed in extensively treated patients as well. There is a strong clinical suggestion of at least partial noncross-resistance with doxorubicin. Taxol is a very promising agent for the treatment of metastatic breast cancer; its optimal application in this disease will be the subject of future trials.
authors.affiliation: Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
authors.forename: A D
authors.initials: AD
authors.lastname: Seidman
authors.forename: L
authors.initials: L
authors.lastname: Norton
authors.forename: B S
authors.initials: BS
authors.lastname: Reichman
authors.forename: J P
authors.initials: JP
authors.lastname: Crown
authors.forename: T J
authors.initials: TJ
authors.lastname: Yao
authors.forename: T B
authors.initials: TB
authors.lastname: Hakes
authors.forename: D E
authors.initials: DE
authors.lastname: Lebwohl
authors.forename: T A
authors.initials: TA
authors.lastname: Gilewski
authors.forename: C A
authors.initials: CA
authors.lastname: Hudis
authors.forename: A
authors.initials: A
authors.lastname: Surbone
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000473:pathology / Q000628:therapy*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D012074:Remission Induction; D016879:Salvage Therapy
chemical_list: D016179:Granulocyte Colony-Stimulating Factor; D017239:Paclitaxel